As a result, the ORR of the 39 patients with advanced GC who received apatinib plus PD-1 blockades at present was 20.5%, DCR was 69.2%, and the median PFS was 3.9 months, which was proved to be an encouraging efficacy and promising PFS numerically. Here, PDCD1 is linked to gastric cancer.